In last trading session, Moderna Inc (NASDAQ:MRNA) saw 11.73 million shares changing hands with its beta currently measuring 2.00. Company’s recent per share price level of $27.72 trading at $0.56 or 2.06% at ring of the bell on the day assigns it a market valuation of $10.69B. That closing price of MRNA’s stock is at a discount of -514.97% from its 52-week high price of $170.47 and is indicating a premium of 3.32% from its 52-week low price of $26.80. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 9.61 million shares which gives us an average trading volume of 11.65 million if we extend that period to 3-months.
For Moderna Inc (MRNA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.89. Splitting up the data highlights that, out of 17 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 12 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Moderna Inc (NASDAQ:MRNA) trade information
Upright in the green during last session for gaining 2.06%, in the last five days MRNA remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $27.72 price level, adding 14.89% to its value on the day. Moderna Inc’s shares saw a change of -33.33% in year-to-date performance and have moved -11.94% in past 5-day. Moderna Inc (NASDAQ:MRNA) showed a performance of -8.73% in past 30-days. Number of shares sold short was 46.88 million shares which calculate 3.8 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 55 to the stock, which implies a rise of 49.6% to its current value. Analysts have been projecting 45 as a low price target for the stock while placing it at a high target of 69. It follows that stock’s current price would drop -62.34% in reaching the projected high whereas dropping to the targeted low would mean a loss of -62.34% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -42.94% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -9.79% while estimates for its earnings growth in next 5 years are of 14.34%.
Moderna Inc (NASDAQ:MRNA)’s Major holders
Insiders are in possession of 7.27% of company’s total shares while institution are holding 72.51 percent of that, with stock having share float percentage of 78.19%. Investors also watch the number of corporate investors in a company very closely, which is 72.51% institutions for Moderna Inc that are currently holding shares of the company. BAILLIE GIFFORD & CO is the top institutional holder at MRNA for having 43.45 million shares of worth $5.16 billion. And as of 2024-06-30, it was holding 11.3149 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 39.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.3568 of outstanding shares, having a total worth of $4.7 billion.
